Give your patients a source you can stand behind
When patients ask about peptides, they're already searching — and too often the answers come from Reddit threads, TikTok, and vendor marketing dressed up as science. PepSense gives your clinic a single, source-cited place to send them: an AI answer engine built on 300,000+ published peptide studies and 200+ compound profiles, so patients arrive at their next visit informed instead of misinformed.
One link instead of a rabbit hole
Redirect the 'I read about this online' conversation to a source-cited answer engine built on 300,000+ published studies — not Reddit, TikTok, or vendor marketing. Patients arrive informed, with the evidence and its limits laid out plainly.
Regulatory status, explained honestly
Real-time tracking of FDA actions in plain English, including the July 2026 PCAC docket. Patients learn that a non-binding advisory vote is not legalization, and that timelines run 12–18 months minimum — no hype, no false urgency.
A complement, never a replacement
PepSense is not a medical service and does not diagnose, prescribe, or recommend use. It handles the educational first pass so your staff can focus on clinical judgment — the decisions that belong with a licensed provider.
Peptide questions have become part of the visit whether or not your clinic works with these compounds. A patient reads about BPC-157 or MOTS-c somewhere online, and staff end up spending appointment time untangling claims, correcting overstated benefits, and explaining what the evidence actually shows. PepSense handles the first pass of that conversation: every answer distinguishes preclinical (in-vitro and animal) findings from human clinical trials from FDA-approved drugs, and cites specific studies by author, journal, and year so patients can see where a claim comes from — and where the evidence stops.
The platform also tracks regulatory reality in plain language, which is where patient confusion runs deepest. Many of the compounds patients ask about are currently unscheduled or research-use-only, and several — BPC-157, TB-500, KPV, MOTS-c, emideltide, epitalon, and semax — are on the FDA Pharmacy Compounding Advisory Committee docket for the July 23–24, 2026 vote on whether to recommend them toward the 503A Bulks List. PepSense explains what that vote is and isn't: it's non-binding, roughly step two of six in FDA rulemaking, and even a favorable outcome means a realistic 12–18 months minimum before any legal compounding availability. Patients get the honest timeline instead of a hype cycle.
To be direct about what this tool is not: PepSense is not a medical service, not a pharmacy, and not a telehealth provider. It does not diagnose, prescribe, recommend human use of any compound, or provide dosing. It is a patient-education resource — an encyclopedia, not an advisor. It informs the conversation between you and your patient; it never replaces your clinical judgment, and every response reinforces that individual medical decisions belong with a licensed provider.
For your clinic, the practical value is reduced staff burden and better-prepared patients. Instead of fielding the same foundational questions in appointment after appointment, you can point patients to a resource that answers them accurately, frames evidence honestly, and sends them back to you for the decisions that actually require a clinician. Link it from your patient portal, include it in intake materials, or simply name it when the topic comes up.